Pharmacological characterization of a novel ENaCα siRNA (GSK2225745) with potential for the treatment of cystic fibrosis

Molecular Therapy Nucleic Acids

Volumn 2, Issue , 2013, Pages e65-

  Clark, Kenneth L ^a   Hughes, Stephen A ^a   Bulsara, Pallav ^a   Coates, Jill ^a   Moores, Kitty ^a   Parry, Joel ^a   Carr, Michael ^a   Mayer, Ruth J ^a   Wilson, Paul ^a   Gruenloh, Chris ^a   Levin, Daren ^a   Darton, Jill ^a   Weber, Wolf Michael ^b   Sobczak, Katja ^b   Gill, Deborah R ^c   Hyde, Stephen C ^c   Davies, Lee A ^c   Pringle, Ian A ^c   Sumner Jones, Stephanie G ^c   Jadhav, Vasant ^d   Jamison, Sharon ^d   Strapps, Walter R ^d   Pickering, Victoria ^d   Edbrooke, Mark R ^a   more..

^a GLAXOSMITHKLINE   (United Kingdom)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cystic fibrosis; ENaC; GSK2225745; SiRNA; Therapeutic

Indexed keywords

EPITHELIAL SODIUM CHANNEL; EPITHELIAL SODIUM CHANNEL BLOCKING AGENT; GSK 2225745; MESSENGER RNA; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 7; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG POTENCY; DRUG SCREENING; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOSTIMULATION; LUNG DISEASE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84878888912     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2012.57     Document Type: Article

References (27)

1. Davis, PB, Yasothan, U and Kirkpatrick, P (2012). Ivacaftor. Nat Rev Drug Discov 11: 349-350.
2. Clunes, MT and Boucher, RC (2007). Cystic Fibrosis: The Mechanisms of Pathogenesis of an Inherited Lung Disorder. Drug Discov Today Dis Mech 4: 63-72. (Pubitemid 351966331)
3. Hirsh, AJ (2002). Altering airway surface liquid volume: inhalation therapy with amiloride and hyperosmotic agents. Adv Drug Deliv Rev 54: 1445-1462. (Pubitemid 35378659)
4. Caci, E, Melani, R, Pedemonte, N, Yueksekdag, G, Ravazzolo, R, Rosenecker, J et al. (2009). Epithelial sodium channel inhibition in primary human bronchial epithelia by transfected siRNA. Am J Respir Cell Mol Biol 40: 211-216.
5. Sobczak, K, Segal, A, Bangel-Ruland, N, Semmler, J, Van Driessche, W, Lindemann, H et al. (2009). Specific inhibition of epithelial Na+ channels by antisense oligonucleotides for the treatment of Na+ hyperabsorption in cystic fibrosis. J Gene Med 11: 813-823.
6. Gauvreau, GM, Pageau, R, Séguin, R, Carballo, D, Gauthier, J, D'Anjou, H et al. (2011). Dose-response effects of TPI ASM8 in asthmatics after allergen. Allergy 66: 1242-1248.
7. Zamora, MR, Budev, M, Rolfe, M, Gottlieb, J, Humar, A, Devincenzo, J et al. (2011). RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. Am J Respir Crit Care Med 183: 531-538.
8. Morrissey, DV, Lockridge, JA, Shaw, L, Blanchard, K, Jensen, K, Breen, W et al. (2005). Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 23: 1002-1007. (Pubitemid 41114035)
9. Morrissey, DV, Blanchard, K, Shaw, L, Jensen, K, Lockridge, JA, Dickinson, B et al. (2005). Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology 41: 1349-1356. (Pubitemid 40770288)
10. Judge, AD, Bola, G, Lee, AC and MacLachlan, I (2006). Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol Ther 13: 494-505. (Pubitemid 43257617)
11. Wagner, H and Bauer, S (2006). All is not Toll: new pathways in DNA recognition. J Exp Med 203: 265-268.
12. Ritter, M, Mennerich, D, Weith, A and Seither, P (2005). Characterization of Toll-like receptors in primary lung epithelial cells: strong impact of the TLR3 ligand poly(I:C) on the regulation of Toll-like receptors, adaptor proteins and inflammatory response. J Inflamm (Lond) 2: 16.
13. Goodchild, A, Nopper, N, King, A, Doan, T, Tanudji, M, Arndt, GM et al. (2009). Sequence determinants of innate immune activation by short interfering RNAs. BMC Immunol 10: 40.
14. Forsbach, A, Nemorin, JG, Montino, C, Müller, C, Samulowitz, U, Vicari, AP et al. (2008). Identification of RNA sequence motifs stimulating sequence-specific TLR8-dependent immune responses. J Immunol 180: 3729-3738.
15. Love, KT, Mahon, KP, Levins, CG, Whitehead, KA, Querbes, W, Dorkin, JR et al. (2010). Lipidlike materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci USA 107: 1864-1869.
16. Southam, DS, Dolovich, M, O'Byrne, PM and Inman, MD (2002). Distribution of intranasal instillations in mice: effects of volume, time, body position, and anesthesia. Am J Physiol Lung Cell Mol Physiol 282: L833-L839. (Pubitemid 34665600)
17. Zimmermann, TS, Lee, AC, Akinc, A, Bramlage, B, Bumcrot, D, Fedoruk, MN et al. (2006). RNAi-mediated gene silencing in non-human primates. Nature 441: 111-114.
18. Jain, L, Chen, XJ, Malik, B, Al-Khalili, O and Eaton, DC (1999). Antisense oligonucleotides against the alpha-subunit of ENaC decrease lung epithelial cation-channel activity. Am J Physiol 276(6 Pt 1): L1046-L1051. (Pubitemid 29321183)
19. Sobczak, K, Bangel-Ruland, N, Leier, G, Semmler, J, Fremerey, J and Weber, WM (2010). Antisense oligonucleotides as potent molecules for the long-term inhibition of ENaC expression. Acta Physiologica 198: S677, P-SUN-42.
20. Yueksekdag, G, Drechsel, M, Rössner, M, Schmidt, C, Kormann, M, Illenyi, MC et al. (2010). Repeated siRNA application is a precondition for successful mRNA gammaENaC knockdown in the murine airways. Eur J Pharm Biopharm 75: 305-310.
21. Stewart, AP, Haerteis, S, Diakov, A, Korbmacher, C and Edwardson, JM (2011). Atomic force microscopy reveals the architecture of the epithelial sodium channel (ENaC). J Biol Chem 286: 31944-31952.
22. Bangel-Ruland, N, Sobczak, K, Christmann, T, Kentrup, D, Langhorst, H, Kusche-Vihrog, K et al. (2010). Characterization of the epithelial sodium channel delta-subunit in human nasal epithelium. Am J Respir Cell Mol Biol 42: 498-505.
23. Li, T and Folkesson, HG (2006). RNA interference for alpha-ENaC inhibits rat lung fluid absorption in vivo. Am J Physiol Lung Cell Mol Physiol 290: L649-L660. (Pubitemid 43725070)
24. Pei, Y, Hancock, PJ, Zhang, H, Bartz, R, Cherrin, C, Innocent, N et al. (2010). Quantitative evaluation of siRNA delivery in vivo. RNA 16: 2553-2563.
25. Camilleri, P, Feiters, MC, Kirby, AJ, Ronsin, GAB, Nolte, RJM and Garcia, CL (2003). Diaminoacid aminoacid polyamine based gemini surfactant compounds. International Patent Application WO2003082809.
26. Blank, U, Clauss, W and Weber, WM (1995). Effects of Benzamil in human cystic fibrosis airway epithelium. Cell Physiol Biochem 5: 385-390. (Pubitemid 26017212)
27. Blank, U, Rückes, C, Clauss, W, Hofmann, T, Lindemann, H, Münker, G et al. (1997). Cystic fibrosis and non-cystic-fibrosis human nasal epithelium show analogous Na+ absorption and reversible block by phenamil. Pflugers Arch 434: 19-24. (Pubitemid 27190429)